Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Carcinoma, Hepatocellular

• Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma
• A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
• Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
• A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
• Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
• Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
• Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
• Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
• BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
• A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
• A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
• Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
• A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
• Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
• Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
• bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
• bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
• Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
• EGCG for Hepatocellular Carcinoma Chemoprevention
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
• A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
• Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
• FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition
• Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation
• Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma
• A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
• A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
• Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
• A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
• Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
• A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
• HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
• Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
• TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
• TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
• H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
• HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
• HACI Combined With Durvalumab, Tremelimumab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
• A Phase II Study of PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
• Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
• Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
• SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
• Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
• Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
• A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
• Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
• HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
• Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
• Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
• Radiofrequency Ablation in Combination With Lenvatinib and Sintilimab
• A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
• AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
• Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
• A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
• Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
• Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
• Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
• TACE-HAIC+Atezolizumab+Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial
• The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation
• Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
• Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
• A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
• SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
• Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
• Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
• SIRT With Tremelimumab and Durvalumab for Resectable HCC
• Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
• Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
• Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatocellular Carcinoma.
• Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma
• AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
• Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
• Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti- PD-(L)1 Antibody on the Treatment of uHCC
• Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
• A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
• Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy
• Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma
• Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
• HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
• Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
• Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy
• Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
• Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
• Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
• Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
• Lenvatinib Plus Sintilimab vs. Lenvatinib for Advanced HCC Treated With TACE
• KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
• A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
• A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma
• Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
• Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
• HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
• Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma
• AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
• Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
• Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
• Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
• TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
• TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
• Phase 1b Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma
• Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
• Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
• LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial
• Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
• Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
• Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
• Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment
• Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
• A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
• HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
• HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
• HAIC Combined With Targeted Therapy and Immunotherapy as Down-stage Therapy of LT
• TACE With Dicycloplatin(TP21) in Unresectable HCC
• Neoadjuvant Anti-PD1 in HCC
• Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib
• Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
• Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
• Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
• Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
• A Phase 2, Open-Label Study of ABSK-011 Plus Atezolizumab to Assess Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy in Patients With Advanced or Unresectable Hepatocellular Carcinoma
• Durvalumab and Tremelimumab in Resectable HCC
• Phase 1b/2 Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
• Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
• T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
• A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
• Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
• mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
• Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma (HCC)
• A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
• Efficacy and Safety of T+A+RAD in HCC
• A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
• Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
• A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)
• A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
• Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
• A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
• Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
• Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
• NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
• TACE Combined With Penpulimab and Anlotinib for Advanced HCC
• IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
• A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
• Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors
• Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
• Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
• A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
• A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
• Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable HCC
• Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
• HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
• Postoperative Adjuvant Therapy of HCC Based on PD-1
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
• Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
• HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
• Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
• Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
• A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
• Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• DEB-TACE+HAIC vs. HAIC for Large HCC
• CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
• TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
• Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
• Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
• HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
• Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
• VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
• Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
• TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
• A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
• Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
• A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer
• Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
• Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
• Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
• Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
• Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
• Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma
• GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
• 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
• Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
• Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
• Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
• Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
• Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
• Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
• HAIC Combine With Lenvatinib and Camrelizumab for Advanced HCC With PVTT
• Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
• Donafenib Plus Sintilimab for Advanced HCC
• Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
• A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
• Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio
• Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)
• HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
• Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
• The Efficacy and Safety of Retreatment With HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
• Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study
• Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
• Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative
• TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
• Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)
• Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
• Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma
• Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy
• A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
• Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
• Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
• Hepatocellular Carcinoma Imaging Using PSMA PET/CT
• Role of DEB-TACE Versus c-TACE in Treatment of HCC
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
• Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
• Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
• A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
• Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC
• TheraSphere With and Without Durvalumab and Tremelimumab for HCC
• Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
• Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
• HMBD-001 in Advanced HER3 Positive Solid Tumours
• Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
• Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
• Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
• GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
• The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
• A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
• Immunotherapy for Advanced Liver Cancer
• HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Advanced Unresectable HCC
• IMC001 for Clinical Research on Advanced Digestive System Malignancies
• Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
• A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
• Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma
• 18F-DCFPyL PET/CT in Hepatocellular Carcinoma
• Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
• to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
• Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
• GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
• Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
• The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
• Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
• TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
• TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
• A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
• A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
• TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors
• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
• Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
• TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)
• DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
• A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
• Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
• Adjuvant Therapy With Anlotinib for HCC
• Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab Versus HAIC Alone for Advanced Hepatocellular Carcinoma
• Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
• Low Dose ICG for Biliary Tract and Tumor Imaging
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
• Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
• SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
• Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
• Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
• TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
• T-Cell Therapy (ECT204) in Adults With Advanced HCC
• SBRT + Atezolizumab + Bevacizumab in Resectable HCC
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
• Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
• Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
• cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
• The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy
• Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
• A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
• Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
• A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
• Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
• PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
• Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial
• Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
• The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
• Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
• Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
• Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma
• TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study
• Regorafenib and Nivolumab Combined Versus TACE in Intermediate-Stage HCC Beyond Up-to-7 (RENOTACE)
• A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
• Intra-tumor Injection of Drug-eluting Microspheres
• Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
• 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
• Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With BI 754091 to Patients With Advanced Solid Tumors Having the B7-H6 Marker
• Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
• Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
• Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
• Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
• A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
• Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
• Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC
• A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
• Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
• A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
• Safety, Tolerability and Anti-tumour Activity Study of MTL-CEBPA Plus Sorafenib
• Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
• Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
• Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
• Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
• Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Thera
• HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial
• Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
• IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
• Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
• Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
• HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
• Perioperative Therapy for Hepatocellular Carcinoma
• Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma
• RFA Combined With PD-1 in HCC: Phase II Study
• Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
• A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
• A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
• ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
• Study of INCB086550 in Select Solid Tumors
• HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
• HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
• Tislelizumab Neo-adjuvant Treatment for Resectable RHCC
• SynOV1.1 Intratumoral Injection Study
• Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
• Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
• Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients
• KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
• TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
• TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
• TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
• TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
• Cabozantinib in Hepatocellular Carcinoma
• Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
• Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
• An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
• The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
• SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
• TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
• NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
• Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
• HepATocellular Cancer Hcv Therapy Study
• The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
• Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
• A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
• Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer
• Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
• Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis
• Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design
• A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
• Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
• Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
• The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to Lenvatinib Treatment
• Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
• Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
• TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
• A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
• Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
• Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
• Optimization for Regorafenib in HCC
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
• A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
• Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
• Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
• To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
• Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
• Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
• Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
• Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients
• A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
• Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma
• Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
• Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
• A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
• SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
• Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
• Study of SRF388 in Patients With Advanced Solid Tumors
• Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
• Itacitinib in Advanced Hepatocellular Carcinoma
• A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
• A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Me
• ATG-008 Combined With Toripalimab in Advanced Solid Tumors
• A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
• Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
• Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
• "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
• Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
• GEN2 Directed Cancer Immunotherapy Trial
• Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
• PSMA PET/MRI or PSMA PET/CT for Evaluation of Hepatocellular Carcinoma
• Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma
• TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma
• A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma
• Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
• Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
• Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
• Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
• Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
• DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
• Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
• Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
• Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
• P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
• DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
• Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
• Longitudinal Immune-phenotyping of HCC Following MK-3475
• Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
• Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
• MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
• Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
• The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer
• A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
• A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma
• RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
• Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
• Atezolizumab Plus Bevacizumab With HCC and HBV Infection
• The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol
• Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
• Neoadjuvant Therapy for Hepatocellular Carcinoma
• Erlotinib for Hepatocellular Carcinoma Chemoprevention
• A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
• Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
• Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
• Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT
• Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
• Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)
• Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
• Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
• Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
• HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
• Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
• Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
• Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC
• Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
• Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
• Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
• A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
• A Study of LY3435151 in Participants With Solid Tumors
• T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
• Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
• Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
• Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
• TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)
• The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
• Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
• Nivolumab Combined With BMS-986253 in HCC Patients
• Effectiveness of Drug Eluting TACE in Primary HCC
• Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
• HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
• Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
• Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
• High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
• RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
• Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
• Neoadjuvant TACE With or Without RT for HCC Involving PVTT
• SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
• SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
• Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC
• A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
• Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
• YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
• TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma
• Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
• Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma
• 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma
• 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
• Albumin for Hepatocellular Carcinoma
• A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
• A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
• Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant
• Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
• Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
• A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
• A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
• Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
• Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
• Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
• A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
• Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma
• TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
• Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
• ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
• Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
• Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
• HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
• Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
• Thermal Ablation Followed by Immunotherapy for HCC
• Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
• Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
• Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
• A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
• Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy
• A Study of PTX-9908 Injection for Non-resectable HCC With TACE
• HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
• Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
• HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
• A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
• A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
• The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma
• Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
• Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
• TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
• Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
• A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
• HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
• HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
• Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
• HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
• Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors
• IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
• Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
• Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
• Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
• A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
• Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
• Radiotherapy/Apatinib for Adjuvant Treatment of HCC Patients receIved Curative reSEction With Microvascular Invasion
• Irradiation Stent Placement Plus TACE for HCC and PVTT
• Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
• SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
• Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
• Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
• BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
• A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
• APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
• IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
• The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
• DKN-01 Inhibition in Advanced Liver Cancer
• CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
• Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation
• Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
• This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
• Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
• TACE-HAIC vs. HAIC for Potentially Resectable HCC
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
• CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
• SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
• Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
• QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
• Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
• Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
• The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
• A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
• Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
• Expanding Phase III Study of Tyroserleutide for Injection
• A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
• Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma
• The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
• Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
• Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
• Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
• Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
• Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)
• Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
• HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
• A Phase II Study of PTS100 in Primary HCC Patients
• TCR-engineered T Cells in Solid Tumors: IMA202-101
• Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
• An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
• A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
• Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
• Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
• Pembrolizumab in Hepatocellular Carcinoma
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
• Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
• The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
• Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
• Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
• Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
• Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment
• Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
• A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
• Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
• SBRT or TACE for Advanced HCC
• Pembrolizumab as Neoadjuvant Treatment in HCC
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
• A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
• Study of Pembrolizumab and Radiotherapy in Liver Cancer
• Study of GNS561 in Patients With Liver Cancer
• Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
• Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
• Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
• Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
• Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
• A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
• Treatment of Advanced Hepatocellular Carcinoma
• Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge
• Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma
• Treatment of Intermediate-stage Hepatocellular Carcinoma
• TACE Emulsion Versus Suspension
• Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection
• Combination of TATE and PD-1 Inhibitor in Liver Cancer
• Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
• Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
• Meclizine for Hepatocellular Carcinoma
• The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
• Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
• Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
• Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
• Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
• The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction
• Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
• Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
• IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
• Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
• Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
• The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Contr
• The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
• Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
• Celebrex and Metformin for Postoperative Hepatocellular Carcinoma
• Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
• Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
• Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
• Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
• Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
• Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
• Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver
• TATE Versus TACE in Intermediate Stage HCC
• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
• A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
• Novel Gallium Imaging in Hepatocellular Carcinoma
• Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
• Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
• Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
• Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
• Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
• A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
• Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
• Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
• Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
• Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
• Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
• Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
• Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
• Paediatric Hepatic International Tumour Trial
• Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis
• A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
• Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
• Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
• Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
• The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.
• Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil
• Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma
• HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
• Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis
• Circulating Tumor Cells and Tumor DNA in HCC and NET
• Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
• Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
• Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
• RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma
• Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
• DAA in the Risk of Recurrence After Curative Treatment of HCC
• A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
• Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
• Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
• Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
• A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
• Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma
• Randomized Phase II Trial of Chemoembolization and Sorafenib
• Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
• Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
• FDGal PET/CT to Detect Hepatocellular Carcinoma
• Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
• Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
• A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
• HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
• Chemoembolization for Hepatocellular Carcinoma
• The Combination Effect of Statin Plus Metformin on Relapse-free
• The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
• Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
• A Study of Anlotinib in Patients With Hepatocellular Carcinoma
• Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma
• Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
• TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
• Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma
• Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
• A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
• Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
• Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection
• Contrast-enhanced Ultrasound Evaluation of Chemoembolization
• Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
• Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)
• Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
• Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
• Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
• Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
• A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
• Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
• Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC
• Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
• First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
• Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
• A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
• Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
• Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
• Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
• [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
• An Open Study Assessing the Safety and Tolerability of U3-1784
• Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and / or Microvascular Invasion
• CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors (Keynote 596)
• Metformin Plus Sorafenib for Advanced HCC
• Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
• A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
• Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
• Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
• Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
• Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
• Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
• Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
• TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
• HCC Patient Preferences in Japan
• Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma
• Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
• Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
• Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
• MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
• A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
• An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
• MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
• A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
• Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
• p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
• Trial of TRC105 and Sorafenib in Patients With HCC
• Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization
• 11C-acetate for Treatment Response After Radiotherapy for HCC
• Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
• Prophylactic Antibiotics Before RFA for HCC
• Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
• TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
• A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
• Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
• Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
• Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.
• LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
• Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients
• Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
• Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
• Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
• A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
• Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcin
• Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
• Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
• HR Combined With FOLFOX4 for HCC With PVTT
• Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
• Adjuvant Therapies for Patients With HCC and MVI
• HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
• A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
• RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC
• Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma
• Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
• A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
• Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
• Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
• Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
• Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
• Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
• Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
• Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy
• A Study of rSIFN-co in Subjects With Advanced Solid Tumors
• A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
• A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
• Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
• Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC
• Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
• FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
• Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
• Primary Prevention Hepatocellular Carcinoma by Metformin
• Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
• Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
• Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
• Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma
• Combine TACE and RFA Versus TACE Alone for HCC With PVTT
• Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
• A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
• Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
• Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
• A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
• Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
• Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma
• A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
• Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
• A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
• A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
• A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
• Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
• Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
• The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
• A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
• Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
• Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
• Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
• Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
• A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
• Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
• Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
• Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
• LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
• PROLIFICA - West African Treatment Cohort for Hepatitis B
• Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
• Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
• c-Met Second-Line Hepatocellular Carcinoma
• Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
• Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
• Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
• Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
• Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
• Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
• To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
• Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
• Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
• A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
• 3-Tesla MRI Response to TACE in HCC (Liver Cancer)
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
• Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
• A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
• Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study
• Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
• Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
• Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
• Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
• Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
• A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
• Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
• The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
• Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
• 24hr Imaging Of HCC After EOVIST
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
• TACE as an Adjuvant Therapy After Hepatectomy for HCC
• Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
• Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
• The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma
• A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
• Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery
• Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
• Urea Cream Treatment Sorafenib-Associated HSFR in HCC
• Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
• Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
• Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
• Preoperative Pain Control in Liver Surgery Patients
• Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
• Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
• A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurr
• Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
• Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
• Sorafenib Chemoembolization Evaluation Controlled Trial
• Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
• Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
• Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC
• A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
• Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
• Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
• Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
• TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
• Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
• Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
• Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
• Tremelimumab With Chemoembolization or Ablation for Liver Cancer
• HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
• Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
• Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
• A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
• Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
• P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.
• Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
• Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
• DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
• A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
• Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
• Sorafenib + mFOLFOX for Hepatocellular Carcinoma
• Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
• Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
• A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
• Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
• Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
• A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
• SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
• Sorafenib for Residue Disease After Resection With Curative Intent
• Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
• A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
• Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
• A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
• Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
• TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
• the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
• Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
• Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
• Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
• A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
• Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
• STA-9090 in Patients With Advanced Hepatocellular Cancer
• Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
• Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
• Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
• Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
• Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
• Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
• Hepatic Xenetix-CT Perfusion
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
• Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
• TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
• Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
• The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List
• Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
• Temsirolimus as Second-line Therapy in HCC
• Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
• A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
• Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma
• Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
• Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
• Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
• S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
• A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
• Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
• Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
• MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
• Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
• Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
• Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
• Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
• Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
• SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma
• Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
• Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
• A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)
• A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
• Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma
• Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
• Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma
• A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
• MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
• Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
• Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
• Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
• Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
• Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
• A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
• PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
• Use of N-Acetylcysteine During Liver Procurement
• Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
• Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
• Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma
• TRC105 for Liver Cancer That Has Not Responded to Sorafenib
• Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)
• Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
• A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
• Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
• Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
• Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
• Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
• A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
• Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma
• Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
• A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
• Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)
• Sorafenib and TRC105 in Hepatocellular Cancer
• Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
• Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
• Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
• Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
• E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
• Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
• Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
• Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
• A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC
• Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
• Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
• Hepatocellular Carcinoma (HCC)_Torisel_
• A Study of LY2157299 in Participants With Hepatocellular Carcinoma
• Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
• MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
• Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy
• A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
• Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
• A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the E
• Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
• Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
• Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
• Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
• ABT-888 and Temozolomide for Liver Cancer
• Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
• Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
• A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
• GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
• Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
• Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
• A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
• Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
• Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
• Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
• Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
• Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
• Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
• Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
• Siliphos in Advanced Hepatocellular Carcinoma
• 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
• Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
• Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
• Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
• Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
• A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
• Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
• Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
• Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma
• Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
• Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
• Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
• Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
• The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma
• Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
• Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
• CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
• Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
• AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
• Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
• Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
• Regulatory Post Marketing Surveillance Study on Nexavar®
• Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
• Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
• Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
• Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
• Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
• Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
• Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
• Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
• Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
• Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
• Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
• Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
• Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
• Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
• Study of Pegylated Human Recombinant Arginase for Liver Cancer
• A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
• A Study to Assess PV-10 Chemoablation of Cancer of the Liver
• Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
• Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
• Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
• TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
• Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
• Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
• Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
• Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
• Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life
• 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
• Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
• Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy
• Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
• Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
• Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
• A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
• Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
• Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
• An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
• XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
• Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
• LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
• Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
• Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
• A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
• Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer
• SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
• Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
• Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
• Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
• First Line Hepato Cellular Carcinoma (HCC)
• A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
• Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
• Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
• Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
• Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
• Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
• Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
• The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma
• Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
• Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
• Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma
• Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
• The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma
• Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
• Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
• A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
• A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection
• Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence
• Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
• Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
• Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
• Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma
• Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
• INSIGHT - Post Marketing Surveillance
• Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
• A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
• Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
• Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma
• Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
• Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
• Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
• Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
• A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
• Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
• Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
• A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
• Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)
• Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
• Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
• A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
• Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
• Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
• Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
• Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
• Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
• Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
• Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
• Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
• Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
• Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients
• Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
• Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
• Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)
• TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
• Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
• Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
• A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
• Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
• Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
• Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
• Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
• Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
• Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
• Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria
• Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
• Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
• A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma
• UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma
• Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
• RAD001 in Advanced Hepatocellular Carcinoma
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
• GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
• Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
• Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
• Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study
• A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
• Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
• Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
• Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
• Sorafenib With TACE to Treat Hepatocellular Carcinoma
• Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients
• Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
• Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
• Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
• Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)
• Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
• Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
• A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma
• A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
• A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
• AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
• Proton Therapy and Bevacizumab for Primary Liver Tumors
• A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
• A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
• Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
• Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
• Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
• A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
• Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
• A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
• Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
• SU011248 in Advanced Hepatocellular Carcinoma
• Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
• A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
• A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
• Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
• Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
• De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
• Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
• A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
• Celecoxib and Erlotinib in Treating Patients With Liver Cancer
• Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
• Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
• Oxaliplatin in Unresectable Hepatocellular Carcinoma
• Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma
• Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
• Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
• Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
• Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
• Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
• Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
• PI-88 in Hepatocellular Carcinoma After Hepatectomy
• An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
• Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
• Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
• Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
• Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
• Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
• A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
• Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors
• A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
• Bevacizumab in Advanced Hepatocellular Carcinoma
• Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
• Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
• Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma
• Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
• Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
• Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
• Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
• Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
• A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
• A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
• SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
• A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
• A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
• Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
• Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
• Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
• TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
• Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
• Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
• Prevention of Recurrent Hepatitis B After Liver Transplantation
• Epirubicin and Thalidomide in Treating Patients With Liver Cancer
• Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
• A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
• T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
• Testing of ADI-PEG in Hepatocellular Carcinoma
• Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
• T900607 in Treating Patients With Unresectable Liver Cancer
• Oxaliplatin in Treating Patients With Liver Cancer
• Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
• Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
• Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
• A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
• Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.
• Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
• Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
• Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
• Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate
• Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
• Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
• Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• DX-8951f in Treating Patients With Liver Cancer
• Chemotherapy in Treating Children With Liver Cancer
• Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
• Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
• Tamoxifen in Treating Patients With Primary Liver Cancer